Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69.
Animals
Antibody Affinity
Antigens, CD
Antigens, Differentiation, T-Lymphocyte
Cross Reactions
Humans
Immunoconjugates
/ administration & dosage
Indium Radioisotopes
Injections, Intravenous
Lectins, C-Type
/ antagonists & inhibitors
Male
Mice
Molecular Imaging
/ methods
Protein Stability
Radiopharmaceuticals
/ administration & dosage
Rats
Recombinant Fusion Proteins
/ administration & dosage
Single Photon Emission Computed Tomography Computed Tomography
/ methods
Tissue Distribution
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 09 2021
27 09 2021
Historique:
received:
20
04
2021
accepted:
19
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
12
2021
Statut:
epublish
Résumé
Due to the wide scale of inflammatory processes in different types of disease, more sensitive and specific biomarkers are required to improve prevention and treatment. Cluster of differentiation 69 (CD69) is one of the earliest cell surface proteins expressed by activated leukocytes. Here we characterize and optimize potential new imaging probes, Affibody molecules targeting CD69 for imaging of activated immune cells. Analysis of candidates isolated in a previously performed selection from a Z variant E. coli library to the recombinant extracellular domain of human CD69, identified one cross-reactive Z variant with affinity to murine and human CD69. Affinity maturation was performed by randomization of the primary Z variant, followed by selections from the library. The resulting Z variants were evaluated for affinity towards human and murine CD69 and thermal stability. The in vivo biodistribution was assessed by SPECT/CT in rats following conjugation of the Z variants by a DOTA chelator and radiolabeling with Indium-111. A primary Z variant with a K
Identifiants
pubmed: 34580321
doi: 10.1038/s41598-021-97694-6
pii: 10.1038/s41598-021-97694-6
pmc: PMC8476556
doi:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, T-Lymphocyte
0
CD69 antigen
0
Immunoconjugates
0
Indium Radioisotopes
0
Lectins, C-Type
0
Radiopharmaceuticals
0
Recombinant Fusion Proteins
0
Indium-111
E9NGC49E0T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19151Informations de copyright
© 2021. The Author(s).
Références
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268
pubmed: 31217020
J Immunol Res. 2015;2015:497056
pubmed: 25759842
Cell Immunol. 1992 Jun;142(1):186-96
pubmed: 1586955
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
Immunology. 1999 May;97(1):159-65
pubmed: 10447727
Periodontol 2000. 2013 Oct;63(1):149-64
pubmed: 23931059
Exp Mol Med. 2017 Mar 24;49(3):e306
pubmed: 28336959
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
J Exp Med. 1994 Nov 1;180(5):1999-2004
pubmed: 7964477
Immunol Rev. 2017 Jul;278(1):87-100
pubmed: 28658550
Biotechnol J. 2019 Apr;14(4):e1800359
pubmed: 30179307
Immunology. 1993 Oct;80(2):281-6
pubmed: 8262555
EJNMMI Res. 2016 Dec;6(1):58
pubmed: 27388754
Cell Immunol. 2002 Nov;220(1):20-9
pubmed: 12718936
Int Immunol. 2004 Jun;16(6):799-809
pubmed: 15096475